| Company Offering Oral Fluid Over-the-Counter HIV-1/2 Rapid Diagnostic Test Internationally and HIV-1 Incidence Test World-wide LAKE OSWEGO, Ore., Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Calypte Biomedical Corporation (Amex: HIV) today announced its support for President George W. Bush's proposal in his recent State of the Union address of an initiative to increase efforts to prevent, treat and ultimately defeat HIV/AIDS. The initiative proposes to distribute rapid HIV tests in areas of the country with the highest rates of newly discovered cases and in the areas having the highest numbers of undetected cases. Distinguishing recent from longer term HIV infection helps define incidence of HIV in a population. The Calypte HIV-1 BED Incidence EIA, a test originally developed by the Centers for Disease Control (CDC), is used in laboratories in the US and world-wide in the evaluation of recent HIV infection. This test is used in population incidence estimates to assist in prevention programs, targeting of educational and treatment resources, monitoring and evaluation and identifying high-risk cohorts for prevention research, including vaccine trials. The CDC and other surveillance laboratories are evaluating recent infections using the Calypte HIV-1 BED Incidence EIA in countries like China, Thailand, Vietnam, Brazil and South Africa. Calypte's Incidence Test also allows Dried Blood Spots to be evaluated. Testing and counseling of persons at risk for HIV infection and subsequent treatment of infected individuals remains a primary tool to curb transmission of the virus. Calypte has developed HIV-1/2 Rapid Tests for use in countries in Africa and Asia that are hardest hit by the HIV pandemic. The Calypte AWARE(TM) HIV-1/2 BSP antibody test uses finger stick blood in an easy to use dipstick format. The Calypte AWARE HIV-1/2 OMT test uses oral fluid as an alternative to blood. An over-the-counter (OTC) version of this test has recently been introduced into the Middle East. These inexpensive tests have demonstrated high accuracy in the target areas where increased testing is needed. Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "Calypte is proud to be participating in the war against HIV/AIDS in such a meaningful and timely way. Our testing products are on the cutting edge for Public Health HIV surveillance with the Calypte HIV-1 BED Incidence EIA and for diagnosis with the Calypte AWARE HIV-1/2 Rapid Tests, now suitable for both the professional market and, in Oral form, for the OTC market." About Calypte Biomedical: Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC. Company Contact: Investor Relations Contact: Theodore R Gwin, Chief Financial Officer Tim Clemensen, (971) 204-0282 Rubenstein Investor Relations email:tgwin@calypte.com Phone: (212) 843-9337 email:tclemensen@rubensteinir.comSOURCE Calypte Biomedical Corporation Theodore R Gwin, Chief Financial Officer, Calypte Biomedical Corporation,+1-971-204-0282, tgwin@calypte.com; Investor, Tim Clemensen, Rubenstein InvestorRelations, +1-212-843-9337, tclemensen@rubensteinir.comhttp://www.prnewswire.com |
Thread abonnieren
